Funder: Breakthrough T1D
Due Dates: October 29, 2025 (Letter of Intent) | January 13, 2026 (Full proposal, invited)
Funding Amounts: Up to $3,000,000 total for up to 3 years; matching funds required from the company; no indirect costs permitted.
Summary: Supports for-profit companies to advance research and clinical trials aligned with Breakthrough T1D’s priorities, accelerating new therapies for type 1 diabetes.
Key Information: LOI required; only invited applicants may submit a full proposal; company matching funds are mandatory.